Sponsored Content | Whitepapers | Mammography | February 28, 2023
Fujifilm’s third generation digital mammography system, ASPIRE Cristalle (known as AMULET Innovality outside the United States), combines state-of-the-art imaging capabilities, a unique hexagonal close pattern detector design, and advanced image processing to maximize image quality and diagnostic accuracy for early detection of breast cancer

Fujifilm’s third generation digital mammography system, ASPIRE Cristalle (known as AMULET Innovality outside the United States), combines state-of-the-art imaging capabilities, a unique hexagonal close pattern detector design, and advanced image processing to maximize image quality and diagnostic accuracy for early detection of breast cancer. This paper describes the advantages of Comfort Comp, a feature designed to augment patient comfort through decreased compression without compromising image quality or workflow.

Although overall mortality rates for breast cancer have decreased in recent years, it remains the most common and the second deadliest cancer among women worldwide. In the US alone, an estimated 284,000 new breast cancer cases and over 44,000 related deaths occurred in 2021, highlighting the urgency of effective preventive strategies.

Early detection can save lives: the 5-year survival rate for breast cancer patients who are diagnosed in the early, localized stage is 99% compared to 26% if diagnosis occurs after spread to the lymph nodes. Regular screening via routine mammograms is our first line of defense and most powerful tool in the fight against breast cancer. However, despite being relatively inexpensive and widely available, approximately 35% of women over age 40 haven’t had a mammogram in more than two years in the US. Screening rates vary greatly around the world, but the fact remains–compliance with periodic screenings continues to be a major challenge to a potentially life-saving strategy.

Inadequate patient education about the importance of early detection and fear of receiving a cancer diagnosis are two of the major factors affecting screening compliance. Pain also ranks high on this list – breast compression during mammography is associated with discomfort and pain, and many patients are reluctant to undergo screening due to the expectation that it will hurt. Improving the patient experience therefore represents our best opportunity to encourage participation in routine screening.

Download the white paper.


Related Content

News | Radiology Business

May 6, 2024 — ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief ...

Time May 06, 2024
arrow
News | Mammography

May 6, 2024 — Enable Me, a VELA Medical company, cited major new research by Siemens Healthineers entitled, “The future ...

Time May 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Breast Density | By Robert L. Bard, MD

Decades since the advent of breast scanning technology, innovations in noninvasive diagnostic imaging provide new ...

Time May 03, 2024
arrow
News | Breast Imaging

May 1, 2024 — Hologic, Inc., a global leader in women’s health, today announced that it signed a definitive agreement to ...

Time May 01, 2024
arrow
News | Breast Imaging

May 1, 2024 — The American College of Radiology (ACR) has issued a statement on the newly released Final USPSTF Breast ...

Time May 01, 2024
arrow
News | Breast Imaging

May 1, 2024 — After the issuance of updated breast screening recommendations by the U.S. Preventive Services Task Force ...

Time May 01, 2024
arrow
Feature | Breast Imaging | Christine Book

April 30, 2024 — The U.S. Preventive Services Task Force (Task Force) today published a final recommendation statement ...

Time April 30, 2024
arrow
Feature | Breast Imaging | By Christine Book

From implementing artificial intelligence effectively, advocating for radiologists, and working tirelessly to expand ...

Time April 29, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
Subscribe Now